Ventral hernia repair with poly-4-hydroxybutyrate mesh.
Margaret A. Plymale, Daniel L. Davenport, Adam Dugan, Amanda Zachem, John Scott Roth
April 2018, Volume 32, Issue 4, pp 1689–1694
Full article: https://www.ncbi.nlm.nih.gov/pubmed/28916979
Biomaterial research has made available a biologically derived fully resorbable poly-4-hydroxybutyrate (P4HB) mesh for use in ventral and incisional hernia repair (VIHR). This study evaluates outcomes of patients undergoing VIHR with P4HB mesh.
An IRB-approved prospective pilot study was conducted to assess clinical and quality of life (QOL) outcomes for patients undergoing VIHR with P4HB mesh. Perioperative characteristics were defined. Clinical outcomes, employment status, QOL using 12-item short form survey (SF-12), and pain assessments were followed for 24 months postoperatively.
31 patients underwent VIHR with bioresorbable mesh via a Rives-Stoppa approach with retrorectus mesh placement. The median patient age was 52 years, median body mass index was 33 kg/m2, and just over half of the patients were female. Surgical site occurrences occurred in 19% of patients, most of which were seroma. Hernia recurrence rate was 0% (median follow-up = 414 days). Patients had significantly improved QOL at 24 months compared to baseline for SF-12 physical component summary and role emotional (p < 0.05).
Ventral hernia repair with P4HB bioresorbable mesh results in favorable outcomes. Early hernia recurrence was not identified among the patient cohort. Quality of life improvements were noted at 24 months versus baseline for this cohort of patients with bioresorbable mesh. Use of P4HB mesh for ventral hernia repair was found to be feasible in this patient population. (ClinicalTrials.gov Identifier: NCT01863030).
Dr. Roth is a speaker for Bard, has grants with Bard, Life Cell, Gore, and MTF, and is a consultant for Life Cell. Dr. Plymale, Dr. Davenport, Mr. Dugan, Ms. Zachem and Dr. Roth have no conflict of interest or financial ties to disclose.